The FDA similarly removed it from its shortage list on February 21, 2025, but this time, it designated off-ramps for production of compounded types right off the bat: Technically, 503A pharmacies have until April 22 to quit making semaglutide drugs, while 503B facilities have until May 22
Stratification of the data revealed that cognitive benefits were seen only in those without dementia at baseline and in trials of more than one year in duration (68)
Bottom line: GLP-1 supplements are all about the marketing
Hence, insulin resistance is linked to prediabetes, type 2 diabetes, and heart disease, all of which become more common as we age
It helps in effective weight management & boosts digestion
BPC-157 is investigational , has limited human clinical data, and any discussion here is presented strictly in a research context , not as a recommendation for personal use.